Director/PDMR Shareholding
(Thomson Reuters ONE) -
Summit Corporation plc
("Summit plc" or "the Company")
DIRECTOR SHARE DEALINGS
Oxford, UK, 05 March 2010,Summit (AIM: SUMM), a leading UK drug discovery
company with a portfolio of partnered drug programmes and a proprietary second
generation iminosugar technology platform, has been notified that Professor
Stephen Davies, Non-executive Director and co-founder of the Company, has today
purchased 50,000 Ordinary shares of one pence each at a price of 4.69 pence per
share.
This purchase is in addition to Professor Davies' purchase of 400,000 Ordinary
shares in November 2009 and a subscription for 1,000,000 Ordinary shares as part
of the successful fundraising that completed in December 2009.
Professor Davies now holds a total of 7,658,748 shares representing 4.61% of the
issued share capital.
- END -
For more information, please contact:
Summit
Steven Lee, PhD
Richard Pye, PhD Tel: +44 (0)1235 443 951
Singer Capital Markets (Nominated
Adviser)
Shaun Dobson / Claes Spång Tel: +44 (0)20 3205 7500
Peckwater PR
Tarquin Edwards Tel: +44 (0)7879 458 364
tarquin.edwards(at)peckwaterpr.co.uk
About Summit plc
Summit is a leading UK based drug discovery company with a portfolio of
partnered drug programmes and a major focus on developing new therapeutics from
its proprietary second generation iminosugar drug discovery platform.
Summit believes iminosugars are the key to gaining access to several disease
mechanisms where classical drug candidates have had little success, and
therefore offer a major opportunity for the discovery and development of new
medicines.
Carbohydrates play critical roles in maintaining correct function of many normal
processes in healthy individuals and provide a wealth of new targets for drug
discovery. Iminosugars have the capability of accessing such targets and offer
the potential of generating new medicines in a variety of major therapy areas.
Summit is currently focussed on metabolic diseases, including diabetes, and
infectious diseases.
Summit has a commercial track record of signing programme agreements and
currently has a product portfolio comprising of a number of drug programmes with
partners including BioMarin Pharmaceuticals, Orient Pharma, Evolva, the Wellcome
Trust and the Lilly TB Drug Discovery Initiative. This portfolio requires no
further investment from Summit but in the future may generate success based
milestone payments of over $160 million and sales royalties rising to a low teen
percentage for the Company.
The company listed on the alternative investment market (AIM) of the London
Stock Exchange in October 2004 - symbol: SUMM. Further information about the
company is available atwww.summitplc.com
[HUG#1391288]
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2010 - 12:18 Uhr
Sprache: Deutsch
News-ID 14407
Anzahl Zeichen: 0
contact information:
Town:
Abingdon,
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Director/PDMR Shareholding"
steht unter der journalistisch-redaktionellen Verantwortung von
Summit Corporation PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
